ASX:NOX Noxopharm (NOX) Stock Price, News & Analysis → Don’t make this retirement mistake (From Sasco Gold LLC) (Ad) Free NOX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.23 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Noxopharm alerts: Email Address Ad Sasco Gold LLCDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. About Noxopharm Stock (ASX:NOX)Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.Read More Ad Sasco Gold LLCDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. NOX Stock News HeadlinesMay 29, 2024 | finance.yahoo.comNoxopharm Limited (NOX.XA)May 27, 2024 | au.investing.comThe morning catch up: US and UK markets on a break as ASX looks set to move higher todayMay 15, 2024 | msn.comASX Small Caps Lunch Wrap: Whose flashed boobies have ruined the fun for everyone this week?April 20, 2024 | nz.finance.yahoo.comNoxopharm Limited (NOX.AX)April 4, 2024 | au.investing.comFIVE at FIVE AU: ASX up as gold ralliesFebruary 28, 2024 | msn.comASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?February 17, 2024 | wsj.comGenetic Technologies Ltd. ADRFebruary 12, 2024 | au.investing.comThe morning catch up: ASX set to rise; Wall Street mixed as investors await inflation dataFebruary 12, 2024 | au.investing.comNoxopharm extends strategic partnership with Hudson Institute of Medical ResearchFebruary 6, 2024 | afr.comNoxopharm LimitedJanuary 10, 2024 | proactiveinvestors.comFIVE at FIVE AU: ASX logs strong day; retail figures better than expectedJanuary 1, 2024 | msn.comASX December Winners: The best 50 stocks as optimism pushes markets near record highNovember 15, 2023 | proactiveinvestors.comNoxopharm boosts cash position with A$6 million R&D rebateOctober 17, 2023 | proactiveinvestors.comNoxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study showsOctober 17, 2023 | msn.comASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 studyOctober 17, 2023 | proactiveinvestors.comNoxopharm soars as study shows SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammationOctober 12, 2023 | au.investing.comNoxopharm and Hudson Institute collaborate on pioneering mRNA researchOctober 11, 2023 | proactiveinvestors.comNoxopharm talks partnership with Hudson Institute of Medical ResearchOctober 4, 2023 | msn.comClosing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastieOctober 4, 2023 | msn.comMarket Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leadsOctober 4, 2023 | fool.com.auASX healthcare stock Noxopharm explodes 165% on FDA newsOctober 3, 2023 | proactiveinvestors.com.auNoxopharm granted US orphan drug status for CRO-67 pancreatic cancer therapySeptember 28, 2023 | msn.comASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trialSeptember 28, 2023 | au.investing.comNoxopharm presents encouraging data on CRO-67 at AACR Pancreatic Cancer conferenceMay 25, 2023 | proactiveinvestors.com.auNoxopharm welcomes preliminary data on Veyonda drug trialSee More Headlines Receive NOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today6/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NOX CUSIPN/A CIKN/A Webwww.noxopharm.com Phone61 2 9144 2223FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.95% Return on Assets-31.32% Debt Debt-to-Equity Ratio0.07 Current Ratio12.81 Quick Ratio8.43 Sales & Book Value Annual Sales$3.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow15.42 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares292,240,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.62 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Gisela MautnerCEO, Executive MD & DirectorMr. Shawn Van Boheemen FCPAJ.P., Chief Financial OfficerMs. Jeanette Bell Ph.D.Chief Operating OfficerDr. John Wilkinson B.Sc.Ph.D., Chief Scientific Officer of OncologyDr. Olivier Laczka B.S.M.Sc., Ph.D., Chief Scientific Officer of InflammationMr. David James Franks BEc (Age 54)C.A., F Fin, J.P., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersFrederick (Fred) BartBought 253,001 shares on 9/14/2023Total: $9,108.04 ($0.04/share)Frederick (Fred) BartSold 3,080,189 sharesTotal: $169,410.40 ($0.06/share) NOX Stock Analysis - Frequently Asked Questions How were Noxopharm's earnings last quarter? Noxopharm Limited (ASX:NOX) announced its earnings results on Thursday, February, 21st. The company reported ($0.04) EPS for the quarter. What other stocks do shareholders of Noxopharm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS), Lincoln Educational Services (LINC) and Immuron (IMRN). This page (ASX:NOX) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredNVDA to close the AI “wealth window’ June 25?On Tuesday, June 25, in front of executives from nearly every major tech company in existence, key leaders at ...Paradigm Direct | Sponsored"If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.""I'd Feel Secure Putting 50% of My Kids' Inheritance in THIS Stock" One Wall Street millionaire bought AAPL...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Noxopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Noxopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.